Table 2 Cost inputs used in the base case analysis
Cost inputs | Costs (€) | Sources |
|---|---|---|
Drug acquisition cost (per day) | ||
Rivaroxaban | 2.16 | Drug price bulletin [36] |
VKA (Acenocoumarol) | 0.05 | Positive Drug List [37] |
Monitoring cost | ||
VKA monitoring visit (1st visit) | 32 | Government Gazzette |
VKA monitoring visit (subsequent visits) | 22 | Government Gazzette |
Other therapies monitoring visit | 10 | Government Gazzette |
Acute treatment event cost | ||
Minor ischemic stroke | 900 | DRGs (N30X) |
Moderate ischemic stroke | 1625 | DRGs (N30Mβ) |
Severe ischemic stroke | 2475 | DRGs (N30Mα) |
Systemic embolism | 1567 | DRGs (K45Mβ, K45Mα)§ |
Intracranial haemorrhage | 2,475 | DRGs (N30Mα) |
Minor extracranial haemorrhage | 257 | DRGs (Ξ21X) |
Major extracranial haemorrhage | 654 | DRGs (Π41M, Π41X)§ |
Acute myocardial infarction | 1,783 | DRGs (K10M, K10X, K31M, K31X, K40M, K40X)§ |
Follow up cost per three month cycle | ||
Major stroke | 1,093 | THESIS study [35] |
Intracranial haemorrhage | 1,093 | Assumption |
Myocardial infarction | 1,296 | THESIS study [35] |